Promoting
regeneration of the
central nervous system

WHO WE ARE

NovaGo Therapeutics is a Swiss clinical-stage biotech company developing human antibody therapeutics for nerve growth and regeneration.

Our lead program targets Nogo-A, a potent inhibitor of nerve-fiber growth, to enhance functional recovery following spinal cord injury — restoring sensation and movement where the central nervous system cannot repair itself.

More about NovaGo

THE CHALLENGE

Spinal cord injury

Spinal cord injury is a devastating neurological disorder caused by disruption of nerve fiber tracts and damage of nerve cells in the spinal cord. It affects people’s lives through loss of sensation and motor paralysis below the site of the injury, often resulting in paraplegia (legs, lower body) or tetraplegia (arms, legs, whole body). Functional recovery is often hindered by the limited capacity of the human central nervous system to self-repair nerve damage.

Explore the science

OUR APPROACH

Stimulating nerve repair

NovaGo develops a human therapeutic antibody to enhance nerve growth and regeneration by blocking Nogo-A, a potent inhibitor of nerve growth. Our antibody candidates have shown to enhance nerve repair and functional recovery in preclinical models. The lead candidate, NG004, is now in a Phase 1b clinical trial for acute spinal cord injury.

See the pipeline

Latest news · 7. January 2025

First patient dosed with NG004 in Phase 1b trial for acute spinal cord injury

NovaGo announces initiation of the SPROUT Phase 1b study of NG004 — the company’s transition to a clinical-stage company with its first asset.

Read more